Dozens of pharmaceutical capsules piled on top of one another to show the scale of the company's drug contributions to the industry. Sanofi (NASDAQ:SNY) is a global healthcare company headquartered in ...

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Attorney General Aaron M. Frey announced a settlement agreement with Sanofi-Aventis U.S. LLC after scrutiny over the ...

An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart problem, in clinical trials, potentially preventing the need for surgery, ...

Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma market. A couple of months ...

The U.S. Food and Drug Administration approved Merilog as ... The FDA granted approval of Merilog to Sanofi (SNY)-Aventis U.S. Published first on TheFly – the ultimate source for real-time ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Regeneron Pharmaceuticals and Sanofi have won Food and Drug Administration priority review of their application seeking expanded approval of their blockbuster anti-inflammatory drug Dupixent for ...

The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...